Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Nov;101(3):115476.
doi: 10.1016/j.diagmicrobio.2021.115476. Epub 2021 Jul 1.

Identification of bacterial co-detections in COVID-19 critically Ill patients by BioFire® FilmArray® pneumonia panel: a systematic review and meta-analysis

Tristan T Timbrook  1 , Kyle D Hueth  2 , Christine C Ginocchio  3
Affiliations
Meta-Analysis

Identification of bacterial co-detections in COVID-19 critically Ill patients by BioFire® FilmArray® pneumonia panel: a systematic review and meta-analysis

Tristan T Timbrook et al. Diagn Microbiol Infect Dis. 2021 Nov.

Abstract

Among critically ill COVID-19 patients, bacterial coinfections may occur, and timely appropriate therapy may be limited with culture-based microbiology due to turnaround time and diagnostic yield challenges (e.g. antibiotic pre-exposure). We performed a systematic review and meta-analysis of the impact of BioFire® FilmArray® Pneumonia Panel in detecting bacteria and clinical management among critically ill COVID-19 patients admitted to the ICU. Seven studies with 558 patients were included. Antibiotic use before respiratory sampling occurred in 28-79% of cases. The panel incidence of detections was 33% (95% CI 0.25 to 0.41, I2=32%) while culture yielded 18% (95% CI 0.02 to 0.45; I2=93%). The panel was associated with approximately a 1 and 2 day decrease in turnaround for identification and common resistance targets, respectively. The panel may be an important tool for clinicians to improve antimicrobial use in critically ill COVID-19 patients.

Keywords: Bacterial; BioFire Pneumonia Panel; COVID-19; Pneumonia; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest T.T. Timbrook and K.D. Hueth are employees of BioFire Diagnostics; C.C. Ginocchio is an employee of bioMérieux and BioFire Diagnostics. Authors report no other conflicts of interest.

Figures

Fig 1
Fig. 1
Forest plot of the pooled incidence of bacterial co-detections by BioFire PN detection.
See this image and copyright information in PMC

References

    1. Alhazzani W, Møller M, Arabi Y, Loeb M, Gong M, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus disease 2019 (COVID-19) Intensive Care Med. 2020;46(5):854–887. - PMC - PubMed
    1. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–160. - PMC - PubMed
    1. Buchan BW, Windham S, Balada-Llasat JM, Leber A, Harrington A, Relich R, et al. Practical comparison of the BioFire FilmArray pneumonia panel to routine diagnostic methods and potential impact on antimicrobial stewardship in adult hospitalized patients with lower respiratory tract infections. J Clin Microbiol. 2020;58(7) - PMC - PubMed
    1. Camelena F, Moy AC, Dudoignon E, Poncin T, Deniau B, Guillemet L, et al. Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19. Diagn Microbiol Infect Dis. 2021;99(1):115183. - PMC - PubMed
    1. Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial superinfections among persons with coronavirus disease 2019: a comprehensive review of data from postmortem studies. Open Forum Infect Dis. 2021;8(3):ofab065. - PMC - PubMed

MeSH terms